Skip to nav Skip to content


The multispecialty team in Moffitt Cancer Center’s Neuro-Oncology Program provides a full array of specialized treatments and services to patients with neurological cancers. As a referring physician, you can rely on Moffitt for:

A multispecialty approach to neurological cancer treatment

When it comes to your patient’s neurological cancer treatment, we know the opinions of multiple experts are better than one. That’s why Moffitt’s neuro-oncology team includes medical oncologists, neurosurgeons, neurologists, radiation oncologists, neuropathologists and multiple other experts who work hand-in-hand to develop an individualized treatment plan for each patient. And, as a high-volume cancer center, Moffitt’s physicians have an unrivaled level of experience in addressing even the most complex and uncommon neurological cancers. It is this experience, combined with Moffitt’s multispecialty approach and advanced treatments, that allows our patients to achieve the best possible outcomes and quality of life.

Clinical trials for neurological cancers

Another factor that sets Moffitt apart from other cancer centers is our comprehensive clinical trial program. Here, our patients have access to the latest breakthroughs in neurological cancer treatments, such as gene therapies and immunotherapies for brain cancer and new approaches to cancer that have spread diffusely in the brain (leptomeningeal disease). No matter what challenges our patients are facing, our experienced, multispecialty team will help them identify the best options for their unique needs. Thanks in part to these efforts, the National Cancer Institute recognizes Moffitt as a Comprehensive Cancer Center.

Refer a patient

Referring physicians are invited to fill out an online form or speak with a physician liaison to refer a patient to Moffitt’s neuro-oncology program. Our team knows the importance of timely cancer treatment, which is why we work hard to respond to all referral requests in less than 48 hours.

check mark symbol Medically reviewed by Michael Vogelbaum, MD, PhD, Program Leader, Chief of Neurosurgery, Neuro-Oncology Program.